Case Report {#S1}
===========

A 75-year-old man with previous history of coronary artery and cerebrovascular disease was admitted to the emergency room of our institution with intense proctalgia, constipation, fecaluria and pneumaturia. He referred loss of more than ten per cent of his weight in one month.

During hospitalization, he also developed dysuria, hematuria, hematochezia and diarrhea. On physical examination, he was in general good clinical condition beside the palpation of soft feces in the rectum.

Initial laboratory tests showed bleeding disorders \[TAP: 14.2 (RV: 11-13), KPTT: 52.9 (RV: 29-42)\] and decrease in albumin \[3.2 (RV: 3.5-5.5)\].

The computed tomography (CT) scan of the abdomen performed on the next day revealed a colovesical fistula and sigmoid tumor, besides enlarged abdominal lymph nodes, leading promptly to a rectosigmoidectomy and partial cystectomy.

After recovery from the surgery, the patient received adjuvant therapy with FLOX,^[@R1]^ which is the regimen reimbursed by the Brazilian national health system. However, after the fourth cycle he developed severe febrile neutropenia requiring intravenous antibiotics and prolonged hospital stay, leading to a decision to suspend further chemotherapy.

The patient remained without any signs of disease relapse until seven months later, when during a routine follow up it was detected a serum tumor marker elevation \[CEA: 55.91 (RV \<5 ng/mL)\], even though the patient remained asymptomatic.

Subsequent abdominal CT scan detected vegetating lesions on the bladder wall and a heterogeneous lesion in the upper pole of the right kidney measuring 4.2× 3.9 cm. On chest CT, there was a nodule in left inferior lobe, adjacent the pulmonary hilum, measuring about 1.9 cm ([Figure 1](#F1){ref-type="fig"}).

Figure 1Abdominal computed tomography showing a heterogeneous lesion in the upper pole of the right kidney, measuring 4.2×3.9 cm.

For further investigation, an urinary tract magnetic resonance imaging (MRI) demonstrated a mass of 5.6×3.6 cm in the middle third of the right kidney, extending to the pelvis.

Initially, the suspicion fell on a new primary tumor, probably an advanced kidney cancer. The patient was then referred to the urology department and underwent tumor punction guided by ultrasound ([Figure 2](#F2){ref-type="fig"}). Histological examination of the kidney biopsy diagnosed tubular adenocarcinoma infiltrative glandular proliferation ([Figure 3](#F3){ref-type="fig"}), representing a sigmoid cancer metastasis.

Figure 2Tumor punction guided by ultrasound.

Figure 3Histological examination of the kidney biopsy diagnosed tubular adenocarcinoma infiltrative glandular proliferation, representing a sigmoid cancer metastasis.

Because of clinical worsening, palliative treatment with capecitabine had begun.

The last abdominal CT confirmed local progression of disease and chest CT showed enlarged thoracic lymph nodes. As the performance status was swiftly deteriorating and the patient was bedridden right after the exams, only best supportive care measured had been taken without any further lines of chemotherapy.

Discussion {#S2}
==========

Metastatic colorectal carcinoma (mCRC) is one of the most common malignant tumors in the Western world.^[@R2]^ Although renal cell carcinoma (RCC) is relatively frequent as a second primary tumor in CRC^[@R3],[@R4]^ the kidney is an unusual site of metastases in CRC.^[@R5],[@R6]^

The most common primary malignancy to involve the kidney is bronchogenic carcinoma, followed by breast and gastrointestinal cancers.^[@R5],[@R7]^

Colorectal cancer was found to involve the kidneys in only 2.7% of postmortem analyses, being part of an advanced systemic disease.^[@R5],[@R8]^ Overall, the frequency of metastases to the kidney in cancer patients is 7--13% in large autopsy series,^[@R7]^ even though it is a much rarer event in clinical practice.

Kidney metastases in mCRC may be generally associated with an unfavorable prognosis, partly due to the accelerated metastatic spread via hematogeneous pathway from the kidney.^[@R8]^ Thus, patients with metastatic CRC and kidney tumors are a diagnostic and therapeutic challenge. Biopsy of the kidney tumor should be performed in patients in good condition with a limited extent of CRC metastases responsive to therapy to distinguish between CRC renal metastasis and secondary primary RCC, since therapeutic decisions can be different.^[@R2]^

Though surgical resection is the only effective treatment for localized RCC, in some circumstances resection may be used for metastatic disease.^[@R9]^

Selected patients with metastatic CRC and secondary primary RCC, taking into account the prognosis of the metastatic tumor, the patient\'s performance status and the presence of co morbidities, may benefit from nephrectomy. Except for these rare cases, nephrectomy has no role in the management of CRC renal metastases.^[@R2]^ Indeed, nephrectomy may compromise the choice of chemotherapy agents that require renal clearance.^[@R5]^

Therefore, systemic chemotherapy remains the treatment of choice for CRC renal metastases. In case of inconclusive biopsy results, management should based on radiological and clinical findings.^[@R2]^
